Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 8Sarcoma, Endometrial Stromal 1Recurrence 1Perivascular Epithelioid Cell Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1ER+ Breast Cancer 1Carcinoma, Intraductal, Noninfiltrating 1Breast Cancer Patients 1Adenosarcoma of the uterus 1

Interventions

Paclitaxel 34Carboplatin 27pembrolizumab 20Bevacizumab 16Letrozole 13Megestrol Acetate 10Cisplatin 9lenvatinib 8olaparib 7dostarlimab 7Metformin 7durvalumab 6abemaciclib 6Radiotherapy 6Everolimus 6niraparib 5Specimen Handling 5Nivolumab 5Medroxyprogesterone Acetate 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Fluorouracil 5Docetaxel 5Biopsy 5temsirolimus 4rucaparib 4Oxaliplatin 4Fulvestrant 4Doxorubicin 4sapanisertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Endometrial Neoplasms × elacestrant × Clear all
NCT07209449 2026-05-22

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
75 enrolled
Gynecologic

Recurrence, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡